Logo image of ATLN

ATLANTIC INTERNATIONAL CORP (ATLN) Stock Fundamental Analysis

NASDAQ:ATLN - Nasdaq - US0485921094 - Common Stock - Currency: USD

2.82  -0.68 (-19.43%)

Fundamental Rating

1

Overall ATLN gets a fundamental rating of 1 out of 10. We evaluated ATLN against 56 industry peers in the Life Sciences Tools & Services industry. ATLN may be in some trouble as it scores bad on both profitability and health. ATLN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ATLN had negative earnings in the past year.
In the past year ATLN has reported a negative cash flow from operations.
ATLN had negative earnings in each of the past 5 years.
In the past 5 years ATLN always reported negative operating cash flow.
ATLN Yearly Net Income VS EBIT VS OCF VS FCFATLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ATLN has a Return On Assets of -110.37%. This is amonst the worse of the industry: ATLN underperforms 92.86% of its industry peers.
Industry RankSector Rank
ROA -110.37%
ROE N/A
ROIC N/A
ROA(3y)-95.29%
ROA(5y)-94.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATLN Yearly ROA, ROE, ROICATLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

ATLN has a worse Gross Margin (10.66%) than 87.50% of its industry peers.
ATLN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ATLN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 10.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-47.23%
GM growth 5Y-28.86%
ATLN Yearly Profit, Operating, Gross MarginsATLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

1

2. Health

2.1 Basic Checks

ATLN does not have a ROIC to compare to the WACC, probably because it is not profitable.
ATLN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ATLN has more shares outstanding
ATLN has a worse debt/assets ratio than last year.
ATLN Yearly Shares OutstandingATLN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ATLN Yearly Total Debt VS Total AssetsATLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 2.36 indicates that ATLN is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.36, ATLN is doing good in the industry, outperforming 60.71% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 2.36
ROIC/WACCN/A
WACC11.69%
ATLN Yearly LT Debt VS Equity VS FCFATLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 0.91 indicates that ATLN may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.91, ATLN is doing worse than 89.29% of the companies in the same industry.
A Quick Ratio of 0.91 indicates that ATLN may have some problems paying its short term obligations.
ATLN has a Quick ratio of 0.91. This is amonst the worse of the industry: ATLN underperforms 82.14% of its industry peers.
Industry RankSector Rank
Current Ratio 0.91
Quick Ratio 0.91
ATLN Yearly Current Assets VS Current LiabilitesATLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 76.83% over the past year.
ATLN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 284.02% yearly.
EPS 1Y (TTM)76.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.87%
Revenue 1Y (TTM)N/A
Revenue growth 3Y1182.14%
Revenue growth 5Y284.02%
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.88%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATLN Yearly Revenue VS EstimatesATLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2024 2025 100M 200M 300M 400M
ATLN Yearly EPS VS EstimatesATLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ATLN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATLN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATLN Price Earnings VS Forward Price EarningsATLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATLN Per share dataATLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATLN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATLANTIC INTERNATIONAL CORP

NASDAQ:ATLN (4/30/2025, 4:05:10 PM)

2.82

-0.68 (-19.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners38.41%
Ins Owner Change8.97%
Market Cap176.02M
Analysts82.86
Price TargetN/A
Short Float %0.82%
Short Ratio1.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.4
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.7
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS7.09
BVpS-0.19
TBVpS-0.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -110.37%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 10.66%
FCFM N/A
ROA(3y)-95.29%
ROA(5y)-94.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-47.23%
GM growth 5Y-28.86%
F-Score3
Asset Turnover3.61
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.47%
Cap/Sales 0.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.91
Quick Ratio 0.91
Altman-Z 2.36
F-Score3
WACC11.69%
ROIC/WACCN/A
Cap/Depr(3y)29.06%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.87%
EPS Next Y21.88%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y1182.14%
Revenue growth 5Y284.02%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-280.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.59%
OCF growth 3YN/A
OCF growth 5YN/A